JP7680955B2 - ロイコトリエン合成阻害剤 - Google Patents

ロイコトリエン合成阻害剤 Download PDF

Info

Publication number
JP7680955B2
JP7680955B2 JP2021538484A JP2021538484A JP7680955B2 JP 7680955 B2 JP7680955 B2 JP 7680955B2 JP 2021538484 A JP2021538484 A JP 2021538484A JP 2021538484 A JP2021538484 A JP 2021538484A JP 7680955 B2 JP7680955 B2 JP 7680955B2
Authority
JP
Japan
Prior art keywords
compound
mmol
etoac
stirred
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021538484A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517316A (ja
JP2022517316A5 (https=
JPWO2020146822A5 (https=
Inventor
エル バーゴイン デイヴィッド
デブルイン エリン
ファナレフ ジュリア
ジー ケン イー ジェイムス
マイケル ラングランズ ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Naegis Pharmaceuticals Inc
Original Assignee
Naegis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naegis Pharmaceuticals Inc filed Critical Naegis Pharmaceuticals Inc
Publication of JP2022517316A publication Critical patent/JP2022517316A/ja
Publication of JP2022517316A5 publication Critical patent/JP2022517316A5/ja
Publication of JPWO2020146822A5 publication Critical patent/JPWO2020146822A5/ja
Priority to JP2024228232A priority Critical patent/JP2025060830A/ja
Application granted granted Critical
Publication of JP7680955B2 publication Critical patent/JP7680955B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021538484A 2019-01-11 2020-01-10 ロイコトリエン合成阻害剤 Active JP7680955B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024228232A JP2025060830A (ja) 2019-01-11 2024-12-25 ロイコトリエン合成阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962791641P 2019-01-11 2019-01-11
US62/791,641 2019-01-11
PCT/US2020/013217 WO2020146822A1 (en) 2019-01-11 2020-01-10 Leukotriene synthesis inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024228232A Division JP2025060830A (ja) 2019-01-11 2024-12-25 ロイコトリエン合成阻害剤

Publications (4)

Publication Number Publication Date
JP2022517316A JP2022517316A (ja) 2022-03-08
JP2022517316A5 JP2022517316A5 (https=) 2023-01-25
JPWO2020146822A5 JPWO2020146822A5 (https=) 2023-01-25
JP7680955B2 true JP7680955B2 (ja) 2025-05-21

Family

ID=71520894

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021538484A Active JP7680955B2 (ja) 2019-01-11 2020-01-10 ロイコトリエン合成阻害剤
JP2024228232A Pending JP2025060830A (ja) 2019-01-11 2024-12-25 ロイコトリエン合成阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024228232A Pending JP2025060830A (ja) 2019-01-11 2024-12-25 ロイコトリエン合成阻害剤

Country Status (11)

Country Link
US (2) US11976052B2 (https=)
EP (1) EP3908278A4 (https=)
JP (2) JP7680955B2 (https=)
KR (2) KR102920650B1 (https=)
CN (1) CN113784713A (https=)
AU (2) AU2020206036A1 (https=)
BR (1) BR112021013637A2 (https=)
CA (1) CA3126021A1 (https=)
MX (1) MX2021007967A (https=)
SG (1) SG11202107080VA (https=)
WO (1) WO2020146822A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025060830A (ja) * 2019-01-11 2025-04-10 ネイジス ファーマシューティカルズ インコーポレイテッド ロイコトリエン合成阻害剤

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003522803A (ja) 2000-02-17 2003-07-29 フィアトリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 鼻炎／結膜炎の治療のために、ロイコトリエンの作用に影響する物質による非鎮静抗ヒスタミン薬の新規な組み合わせ
JP2007500703A (ja) 2003-07-28 2007-01-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンズイミダゾール、ベンズチアゾールおよびベンゾキサゾール誘導体およびｌｔａ４ｈモジュレーターとしてのそれらの使用
JP2008536825A (ja) 2005-03-31 2008-09-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ フェニルおよびピリジルｌｔａ４ｈモジュレータ
JP2011502150A (ja) 2007-10-31 2011-01-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ロイコトリエンａ４ヒドロラーゼのモジュレーターとしてのアリール置換架橋又は縮合ジアミン
JP2011516571A (ja) 2008-04-11 2011-05-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ロイコトリエンａ４加水分解酵素の調節因子としてのチアゾロピリジン−２−イルオキシ−フェニル及びチアゾロピラジン−２−イルオキシ−フェニルアミン
JP2016513126A (ja) 2013-02-20 2016-05-12 エルジー・ライフ・サイエンシーズ・リミテッドＬＧ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． スフィンゴシン−１−リン酸受容体アゴニスト、その製造方法及びそれらを活性成分として含有する医薬組成物
JP2017505327A (ja) 2014-02-06 2017-02-16 アッヴィ・インコーポレイテッド ６−ヘテロアリールオキシ−および６−アリールオキシ−キノリン−２−カルボキシアミドならびにその使用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661499A (en) 1985-06-18 1987-04-28 Merck Frosst Canada, Inc. 2-[(substituted)-phenoxymethyl]quinolines
GB9122590D0 (en) * 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
WO1994006802A1 (fr) 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation medicinale
ES2062943B1 (es) 1993-03-23 1995-11-16 Uriach & Cia Sa J Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas.
US5486612A (en) * 1993-12-14 1996-01-23 Eli Lilly And Company N-benzyl dihydroindole LTD4 antagonists
FR2734265B1 (fr) 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
US5783586A (en) 1996-10-01 1998-07-21 Abbott Laboratories Heteroarylmethoxyphenylthioalkyl carboxylates as inhibitors of leukotriene biosynthesis
EP0968179B1 (en) * 1997-02-25 2002-09-25 Syngenta Participations AG N-sulphonyl and n-sulphinyl amino acid amides as microbiocides
ATE233104T1 (de) * 1997-09-18 2003-03-15 Janssen Pharmaceutica Nv Kondensierte imidazolderivate zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
PL359619A1 (en) 2000-06-23 2004-08-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2004513935A (ja) 2000-11-17 2004-05-13 ノボ　ノルディスク　アクティーゼルスカブ グルカゴンアンタゴニスト／逆アゴニスト
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
US20050070506A1 (en) * 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
WO2004063147A1 (en) 2003-01-10 2004-07-29 Novo Nordisk A/S Salts and solvates of glucagon antagonists
US7329682B2 (en) 2003-04-03 2008-02-12 Ewha University-Industry Collaboration Foundation Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
UA86283C2 (uk) 2005-01-07 2009-04-10 Пфайзер Продактс Инк. Гетероароматичні сполуки хіноліну і їх застосування як інгібіторів pde10
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
US7939528B2 (en) * 2005-10-13 2011-05-10 Glaxosmithkline Llc Heterocycle compounds
DE102006021878A1 (de) 2006-05-11 2007-11-15 Sanofi-Aventis Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2008057280A1 (en) 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
AU2008256922B2 (en) 2007-05-23 2011-07-28 Novartis Ag Raf inhibitors for the treatment of thyroid cancer
US9446995B2 (en) 2012-05-21 2016-09-20 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
WO2009132202A2 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
MX2010013683A (es) 2008-06-13 2011-04-26 Novartis Ag Bencimidazoles sustituidos para neurofibromatosis.
TW201010977A (en) 2008-08-12 2010-03-16 Takeda Pharmaceutical Amide compound
WO2010059163A1 (en) 2008-11-21 2010-05-27 Hassan Hamza Adjustable vacuum relief safety valve system for swimming pools and spas
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
WO2014077401A1 (ja) 2012-11-19 2014-05-22 武田薬品工業株式会社 含窒素複素環化合物
CN104045552B (zh) 2013-03-13 2019-06-11 江苏先声药业有限公司 作为神经保护剂的药用化合物
US20160101106A1 (en) 2013-05-07 2016-04-14 Inhibikase Therapeutics, Inc. Methods for treating hcv infection
SG11201509351UA (en) 2013-06-10 2015-12-30 Bayer Pharma AG Novel compounds for the treatment of cancer
SG11201609050UA (en) * 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
EP3328860B2 (en) 2015-07-28 2022-11-02 UDC Ireland Limited Process for the preparation of benzimidazo[1,2-a]benzimidazoles
BR112018003711A2 (pt) * 2015-08-26 2018-09-25 Texas A & M Univ Sys método para sensibilização de um parasita a um fármaco e método para prevenir infecção sintomática de um paciente por um parasita ou tratar infecção de um paciente por um parasita com um fármaco
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CN107383014B (zh) 2017-06-21 2019-04-30 南方医科大学 一种1H-吡唑并[3,4-d]嘧啶类化合物及其制备方法和应用
EP3908278A4 (en) * 2019-01-11 2022-09-28 Naegis Pharmaceuticals Inc. INHIBITORS OF LEUKOTRIEN SYNTHESIS

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003522803A (ja) 2000-02-17 2003-07-29 フィアトリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 鼻炎／結膜炎の治療のために、ロイコトリエンの作用に影響する物質による非鎮静抗ヒスタミン薬の新規な組み合わせ
JP2007500703A (ja) 2003-07-28 2007-01-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンズイミダゾール、ベンズチアゾールおよびベンゾキサゾール誘導体およびｌｔａ４ｈモジュレーターとしてのそれらの使用
JP2008536825A (ja) 2005-03-31 2008-09-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ フェニルおよびピリジルｌｔａ４ｈモジュレータ
JP2011502150A (ja) 2007-10-31 2011-01-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ロイコトリエンａ４ヒドロラーゼのモジュレーターとしてのアリール置換架橋又は縮合ジアミン
JP2011516571A (ja) 2008-04-11 2011-05-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ロイコトリエンａ４加水分解酵素の調節因子としてのチアゾロピリジン−２−イルオキシ−フェニル及びチアゾロピラジン−２−イルオキシ−フェニルアミン
JP2016513126A (ja) 2013-02-20 2016-05-12 エルジー・ライフ・サイエンシーズ・リミテッドＬＧ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． スフィンゴシン−１−リン酸受容体アゴニスト、その製造方法及びそれらを活性成分として含有する医薬組成物
JP2017505327A (ja) 2014-02-06 2017-02-16 アッヴィ・インコーポレイテッド ６−ヘテロアリールオキシ−および６−アリールオキシ−キノリン−２−カルボキシアミドならびにその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kolasa, Teodozyj et al.，SymmetricalBis(heteroarylmethoxyphenyl)alkylcarboxylic Acids as Inhibitors of LeukotrieneBiosynthesis，Journal of Medicinal Chemistry，2000年，43(17)，pp.3322-3334

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025060830A (ja) * 2019-01-11 2025-04-10 ネイジス ファーマシューティカルズ インコーポレイテッド ロイコトリエン合成阻害剤

Also Published As

Publication number Publication date
EP3908278A4 (en) 2022-09-28
AU2025252635A1 (en) 2025-11-06
JP2022517316A (ja) 2022-03-08
US11976052B2 (en) 2024-05-07
CA3126021A1 (en) 2020-07-16
KR20210123321A (ko) 2021-10-13
CN113784713A (zh) 2021-12-10
BR112021013637A2 (pt) 2021-09-14
KR20260018201A (ko) 2026-02-06
US20220064132A1 (en) 2022-03-03
WO2020146822A1 (en) 2020-07-16
JP2025060830A (ja) 2025-04-10
US20250011293A1 (en) 2025-01-09
SG11202107080VA (en) 2021-07-29
KR102920650B1 (ko) 2026-01-29
MX2021007967A (es) 2021-09-21
EP3908278A1 (en) 2021-11-17
AU2020206036A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
JP7615061B2 (ja) 特発性肺線維症を治療する方法
JP3981357B2 (ja) 第４級アンモニウム化合物および抗ムスカリン剤としてのそれらの使用
JP6218940B2 (ja) キニン系化合物、その光学異性体及びその製造方法と医薬用途
RU2689315C2 (ru) Соль гетероциклического соединения, замещенного галогеном
DE69722258T2 (de) Neue verbindungen nutlich als neuroschützende mittel
US20230391734A1 (en) Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
JP2025060830A (ja) ロイコトリエン合成阻害剤
JP2014522411A (ja) 脳癌を処置するための方法および組成物
JP2002538101A (ja) 肥満症を予防または治療するための薬剤の製造における多環式チアゾール系の使用
US20260027243A1 (en) AMPHIPHILIC COMPOUNDS FOR ATTENUATING NEUROTOXICITY OF AMYLOID-beta OLIGOMERS AND DIAGNOSTIC METHODS
CN107778282B (zh) 喹啉-吲哚衍生物及其在制备治疗阿尔茨海默病的药品中的应用
KR102640385B1 (ko) 고혈압 및/또는 폐 섬유증 치료용 조성물
JP7714251B2 (ja) Ｐｕ．１阻害剤としての化合物
WO2025092340A1 (zh) 吡咯并三嗪类化合物在制备预防和/或治疗纤维化或其相关疾病的药物中的应用
JP2025529076A (ja) ＡｈＲ媒介疾患の治療に使用するタピナロおよびそのアナログ製剤
HK40063173A (en) Method for treating idiopathic pulmonary fibrosis
EA042432B1 (ru) Замещенные фенилсульфонил фенилтриазолтионы и их применение

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20211014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250509

R150 Certificate of patent or registration of utility model

Ref document number: 7680955

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150